Crossmark Global Holdings Inc. Has $978,000 Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Crossmark Global Holdings Inc. raised its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 16.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,487 shares of the company’s stock after purchasing an additional 1,204 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Neurocrine Biosciences were worth $978,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of NBIX. Ashton Thomas Private Wealth LLC acquired a new position in Neurocrine Biosciences during the second quarter valued at $28,000. Innealta Capital LLC purchased a new position in Neurocrine Biosciences during the 2nd quarter valued at about $30,000. New Covenant Trust Company N.A. acquired a new position in shares of Neurocrine Biosciences in the 1st quarter valued at about $32,000. EdgeRock Capital LLC purchased a new stake in shares of Neurocrine Biosciences in the second quarter worth approximately $35,000. Finally, Blue Trust Inc. boosted its holdings in shares of Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after purchasing an additional 220 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a research report on Friday, November 1st. Royal Bank of Canada reduced their price objective on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a research report on Friday, October 4th. Oppenheimer boosted their target price on Neurocrine Biosciences from $216.00 to $219.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. raised their price target on Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Finally, Robert W. Baird boosted their price target on Neurocrine Biosciences from $157.00 to $180.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Five equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $163.91.

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock opened at $122.88 on Friday. The firm has a fifty day moving average price of $118.53 and a two-hundred day moving average price of $132.88. Neurocrine Biosciences, Inc. has a fifty-two week low of $107.84 and a fifty-two week high of $157.98. The company has a market cap of $12.44 billion, a PE ratio of 33.35 and a beta of 0.35.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.